A Single-Dose, Open-Label, Randomized, 4-Way Crossover Study to Characterize the Pharmacokinetics and the Effect of Food of JNJ-31001074 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2010
At a glance
- Drugs Bavisant (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 11 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2009 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.
- 10 Oct 2009 Planned end date changed from 1 Aug 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.